Evidence map›Paper›PMID 41955100›Full record

ArticleSTAR protocols2026

Protocol for generating and characterizing Matrigel-free prostate cancer patient-derived organoids.

Robin Dolgos, Romuald Parmentier, Jing Wang, Arnoud J Templeton, Kirsten D Mertz, Heike Pueschel, Helge Seifert, Ashkan Mortezavi, Tatjana Vlajnic, Cyrill A Rentsch and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Robin DolgosInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Urology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Romuald ParmentierInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Urology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Jing WangInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Urology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Arnoud J TempletonDivision of Medical Oncology, St. Claraspital, Basel, and Faculty of Medicine, University of Basel, Basel, Switzerland.
Kirsten D MertzInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Heike PueschelDepartment of Urology, University Hospital Basel, Basel, Switzerland.
Helge SeifertDepartment of Urology, University Hospital Basel, Basel, Switzerland.
Ashkan MortezaviDepartment of Urology, University Hospital Basel, Basel, Switzerland.
Tatjana VlajnicInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Cyrill A RentschDepartment of Urology, University Hospital Basel, Basel, Switzerland.
Lukas BubendorfInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Clémentine Le MagnenInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland; Department of Urology, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland. Electronic address: clementine.lemagnen@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we present a protocol for the generation of prostate cancer patient-derived organoids (PCa PDOs) in Matrigel-free conditions. We describe steps for sample selection, pathological resection, and tissue dissociation. We then detail procedures for the generation, maintenance, and characterization of the PCa PDOs. Finally, we provide guidance for the processing of PDOs for single-cell RNA sequencing (scRNA-seq) analysis and using the prostate PDO single-cell atlas (PPScA) for both novice and advanced bioinformatic users. For complete details on the use and execution of this protocol, please refer to Dolgos et al.

Indexed as

Cell Culture TechniquesOrganoidsProstatic NeoplasmsCollagenDrug CombinationsHumansLamininMaleProteoglycansCollagenDrug CombinationsLamininmatrigelProteoglycansBioinformaticsCancerCell BiologyMolecular BiologyOrganoids

Identifiers

PMID41955100
PMCPMC13091043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.